Advertisement

PharmacoEconomics

, Volume 35, Issue 2, pp 237–248 | Cite as

Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom

  • Lindsay ClaxtonEmail author
  • Robert Hodgson
  • Matthew Taylor
  • Bill Malcolm
  • Ruth Pulikottil Jacob
Original Research Article

Abstract

Background

Previously developed models in ophthalmology have generally used a Markovian structure. There are a number of limitations with this approach, most notably the ability to base patient outcomes on best-corrected visual acuity (BCVA) in both eyes, which may be overcome using a different modelling structure. Simulation modelling allows for this to be modelled more precisely, and therefore may provide more accurate and relevant estimates of the cost effectiveness of ophthalmology interventions.

Objective

This study aimed to explore the appropriateness of simulation modelling in ophthalmology, using the disease area of wet age-related macular degeneration (wAMD) as an example.

Methods

A de novo economic model was built using a patient-level simulation, which compared ranibizumab with aflibercept in wAMD. Disease progression was measured using BCVA. Health-related quality of life (HRQoL) was estimated using a regression analysis linking BCVA in each eye to utility. The analysis was from the perspective of the National Health Service in the UK. Five different regression models were explored and were based on BCVA in either one eye or both eyes.

Results

The model outputs provide some evidence to support the hypothesis that the analyses using the two-eye models for estimating HRQoL generate a more accurate estimation of incremental quality-adjusted life-years (QALYs) associated with the positive treatment effect for ranibizumab versus aflibercept. Second-order analysis broadly supported these findings, and showed that the variation in incremental costs was slightly lower than in incremental QALYs. The second-order analysis estimated similar incremental costs and a greater overall variation in incremental QALYs than the first-order analysis, suggesting important non-linearities within the model.

Conclusions

This analysis suggests that patient-level simulation models may be well suited to representing the real-world patient pathway in wAMD, particularly when aspects of disease progression cannot be adequately captured using a Markov structure. The benefits of a simulation approach can be demonstrated in the modelling of HRQoL as a function of BCVA in both eyes.

Keywords

Ranibizumab Well Correct Visual Acuity Diabetic Macular Oedema Aflibercept Evidence Review Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The original regression analysis of the Czoski-Murray quality of life dataset was undertaken by David Trueman and Tim Reason at Abacus International, and was funded by Novartis.

The authors would like to thank the IVAN trial investigators for providing the dataset for modelling ranibizumab BCVA progression.

Author contributions

All authors were involved in the conceptualisation of the analysis. LC and RH developed the economic analysis. LC, RH and RPJ contributed equally towards the drafting of the manuscript. All authors provided feedback on each draft of the manuscript. LC will act as the overall guarantor.

Compliance with Ethical Standards

The study was funded and initiated by Novartis Pharmaceuticals UK Ltd. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Ruth Pulikottil-Jacob is an employee of Novartis and Bill Malcolm is an ex-employee of Novartis. Lindsay Claxton and Matthew Taylor are employees of York Health Economics Consortium, which was commissioned by Novartis to develop the study. Robert Hodgson is an ex-employee of York Health Economics Consortium.

Supplementary material

40273_2016_459_MOESM1_ESM.docx (103 kb)
Supplementary material 1 (DOCX 102 kb)

References

  1. 1.
    Bayer. Aflibercept solution for injection for treating wet age-related macular degeneration—Single Technology Appraisal [TA294]. Manufacturer’s Submission, 2013.Google Scholar
  2. 2.
    Cummins E, Fielding S, Johnston R, Rothnie K, Stewart F, Lois N, Burr J, Brazzelli M. Aflibercept solution for injection for the treatment of wet age-related macular degeneration. Aberdeen HTA Group; 2013.Google Scholar
  3. 3.
    Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Southampton Health Technology Assessments Centre; 2006.Google Scholar
  4. 4.
    Edwards SJ, Barton S, Trevor N, Lois N, Nherera L, Hamilton V. Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO): A Single Technology Appraisal. London: BMJ Technology Assessment Group; 2011.Google Scholar
  5. 5.
    Shyangdan DS, Cummins E, Clar C, Ford J, Court R, Lois N, Waugh N. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion—a single technology assessment. Warwick Evidence 2013.Google Scholar
  6. 6.
    Fielding S, Cummins E, Cruickshank M, Fraser C, Lois N, Brazzelli M. Aflibercept for treating diabetic macular oedema. Aberdeen HTA group; 2014.Google Scholar
  7. 7.
    Cummins E, Fielding S, Cruickshank M, Fraser C, Lois N, Brazzelli M. Ranibizumab for the treatment of choroidal neovascularisation associated with pathological myopia. Aberdeen HTA Group; 2013.Google Scholar
  8. 8.
    National Institute for Health and Care Excellence. Aflibercept solution for injection for treating wet age-related macular degeneration. NICE technology appraisal guidance [TA294], 2013.Google Scholar
  9. 9.
    National Institute for Health and Care Excellence. Ranibizumab and pegaptanib for the treatment of wet age-related macular degeneration. NICE technology appraisal guidance [TA155], 2008.Google Scholar
  10. 10.
    Brown GC, Brown MM, Sharma S, Brown HC. Patient perceptions of quality-of-life associated with bilateral vision loss. Int Ophthalmol. 1998;22(5):307–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Butt T, Patient PJ, Tufail A, Rubin GS. Modelling cost effectiveness in neovascular age-related macular degeneration the impact of using contrast sensitivity vs visual acuity. Appl Health Econ Health Policy. 2014;12(3):289–97.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Submacular Surgery Trials Research Group, Solomon SD, Jefferys JL, Hawkins BS, Bressler NM. Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group. Arch Ophthalmol. 2007;125(10):1323–30.CrossRefGoogle Scholar
  14. 14.
    Davis S, Stevenson M, Tappenden P, Wailoo A. NICE DSU Technical Support Document 15: cost-effectiveness modelling using patient-level simulation. 2014.Google Scholar
  15. 15.
    Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomized trial. Lancet. 2013;382(9900):1258–67.CrossRefPubMedGoogle Scholar
  16. 16.
    Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48.CrossRefPubMedGoogle Scholar
  17. 17.
    Malcolm WA, Hodgson R, Glanville J, et al. Indirect treatment comparison of interventions for neovascular (wet) age-related macular degeneration (wet AMD) [Code PSS2]. ISPOR 20th Annual International Meeting. Philadelphia, PA, USA, 2015.Google Scholar
  18. 18.
    Ding Y, Fu H. Bayesian indirect and mixed treatment comparisons across longitudinal time points. Stat Med. 2013;32(15):2613–28.CrossRefPubMedGoogle Scholar
  19. 19.
    Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201.CrossRefPubMedGoogle Scholar
  20. 20.
    Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration. Ophthalmology. 2008;115(1):116–26.CrossRefPubMedGoogle Scholar
  21. 21.
    Frisen L, Frisen M. How good is normal visual acuity? A study of letter acuity thresholds as a function of age. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1981;215(3):149–57.CrossRefPubMedGoogle Scholar
  22. 22.
    Elliott DB, Yang KCH, Whitaker D. Visual acuity changes throughout adulthood in normal, health eyes: seeing beyond 6/6. Optom Vis Sci. 1995;72(3):186–91.CrossRefPubMedGoogle Scholar
  23. 23.
    Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. Value Health. 2009;12(5):793–9.CrossRefPubMedGoogle Scholar
  24. 24.
    PSSRU. Personal Social Services Research Unit. Unit costs of Health and Social Care 2014. http://www.pssru.ac.uk/project-pages/unit-costs/2014/. Accessed Dec 2015.
  25. 25.
    Writing Committee for the UKA-RMDEMRUG. The neovascular age-related macular degeneration database: multicenter study of 92,976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121(5):1092–101.CrossRefGoogle Scholar
  26. 26.
    Novartis Pharmaceuticals UK Limited. LUCENTIS summary of product characteristics.Google Scholar
  27. 27.
    Technology Appraisal TA294. Aflibercept solution for injection for treating wet age-related macular degeneration. Assumptions based on expert opinion and used within NICE costing template.Google Scholar
  28. 28.
    Meads C, Salas C, Roberts T, Moor D, Fry-Smith A, Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degenerations: a systematic review and economic evaluation. Health Technol Assess. 2003;7(9):v–vi, 1–98.Google Scholar
  29. 29.
    Shyangdan D CE, Lois N, Royle P, Waugh N. Dexamethasone implants in the treatment of macular oedema due to retinal vein occlusion: a single technology appraisal. Aberdeen HTA group; 2010.Google Scholar
  30. 30.
    National Life Tables, United Kingdom, 2012-2014: Office for National Statistics; 2015. http://www.ons.gov.uk/ons/rel/lifetables/national-life-tables/2012-2014/index.html. Accessed Dec 2015.
  31. 31.
    Christ SL, Lee DJ, Lam BL, Zheng DD, Arheart KL. Assessment of the effect of visual impairment on mortality through multiple health pathways: structural equation modeling. Investig Ophthalmol Vis Sci. 2008;49(8):3318–23.CrossRefGoogle Scholar
  32. 32.
    Koehler E, Brown E, Haneuse SJ. On the assessment of Monte Carlo error in simulation-based statistical analyses. Am Stat. 2009;63(2):155–62.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999;97:473–511.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Sharma S, Brown GC, Brown MM, et al. Converting visual acuity to utilities. Can J Ophthalmol. 2000;35(5):267–72.CrossRefPubMedGoogle Scholar
  35. 35.
    Bansback N, Czoski-Murray C, Carlton J, Lewis G, Hughes L, Espallargues M, et al. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. Qual Life Res. 2007;16(3):533–43.CrossRefPubMedGoogle Scholar
  36. 36.
    Claxton L, Hodgson R, Malcolm W. A comparison of modelling techniques: Patient simulation vs Markov modelling in ophthalmology. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Congress, Amsterdam, The Netherlands, 2014.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Lindsay Claxton
    • 1
    Email author
  • Robert Hodgson
    • 1
  • Matthew Taylor
    • 1
  • Bill Malcolm
    • 2
  • Ruth Pulikottil Jacob
    • 2
  1. 1.York Health Economics ConsortiumUniversity of YorkYorkUK
  2. 2.Novartis Pharmaceuticals UK LimitedSurreyUK

Personalised recommendations